Amarin Co. plc (AMRN) Downgraded by BidaskClub
Amarin Co. plc (NASDAQ:AMRN) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday.
A number of other brokerages also recently commented on AMRN. Zacks Investment Research upgraded Amarin Co. plc from a “sell” rating to a “hold” rating in a report on Monday, July 3rd. Jefferies Group LLC upped their target price on Amarin Co. plc from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, June 30th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Amarin Co. plc in a report on Thursday, August 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price on shares of Amarin Co. plc in a report on Monday, June 26th. Finally, ValuEngine downgraded Amarin Co. plc from a “hold” rating to a “sell” rating in a report on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $7.35.
Amarin Co. plc (NASDAQ:AMRN) traded down 2.81% on Friday, reaching $3.11. 1,265,718 shares of the company’s stock traded hands. The firm’s 50-day moving average is $3.87 and its 200 day moving average is $3.31. The firm’s market cap is $842.16 million. Amarin Co. plc has a 12 month low of $2.56 and a 12 month high of $4.47.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. Amarin Co. plc’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.07) EPS. Equities analysts predict that Amarin Co. plc will post ($0.22) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/amarin-co-plc-amrn-downgraded-by-bidaskclub/1472397.html.
In other Amarin Co. plc news, General Counsel Joseph T. Kennedy sold 307,911 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total value of $1,231,644.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.72% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of AMRN. Wells Fargo & Company MN increased its position in Amarin Co. plc by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares during the period. Perkins Capital Management Inc. purchased a new position in Amarin Co. plc during the first quarter worth about $110,000. JPMorgan Chase & Co. increased its position in Amarin Co. plc by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 7,580 shares during the period. Private Advisor Group LLC increased its position in Amarin Co. plc by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 1,032 shares during the period. Finally, Airain ltd increased its position in Amarin Co. plc by 382.9% in the second quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 69,081 shares during the period. Institutional investors and hedge funds own 37.57% of the company’s stock.
Amarin Co. plc Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Co. plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Co. plc and related companies with Analyst Ratings Network's FREE daily email newsletter.